Market Overview

Why DiaMedica's Stock Is Trading Higher Today

Share:
Why DiaMedica's Stock Is Trading Higher Today

DiaMedica Therapeutics (NASDAQ: DMAC) shares are trading higher on Wednesday after Maxim Group initiated coverage on the stock with a Buy rating and announced a price target of $14 per share.

DiaMedica Therapeutics is a clinical-stage biopharmaceutical company. It is principally engaged in the business activity of developing treatments for unmet clinical need or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

DiaMedica Therapeutics shares traded up 3.19% at $6.96 at time of publication on Wednesday. The stock has a 52-week high of $8.80 and a 52-week low of $1.70.

Latest Ratings for DMAC

DateFirmActionFromTo
Jul 2020Maxim GroupInitiates Coverage OnBuy
May 2020Craig-HallumMaintainsBuy

View More Analyst Ratings for DMAC
View the Latest Analyst Ratings

 

Related Articles (DMAC)

View Comments and Join the Discussion!

Posted-In: why it's movingPrice Target Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
MRTXHC Wainwright & Co.Maintains257.0
NVDATruist SecuritiesMaintains672.0
NVDASusquehannaMaintains625.0
BLKBMO CapitalMaintains715.0
BLKDeutsche BankMaintains838.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com